Docetaxel second-line therapy in patients with advanced pancreatic cancer: A retrospective study

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2905-2909

  Saif, Muhammad Wasif ^a   Syrigos, Kostas ^b   Penney, Robin ^a   Kaley, Kristin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chemotherapy; Docetaxel; Gemcitabine; Metastatic disease; Pancreatic cancer; Refractory; Salvage therapy

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; EDEMA; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HUMAN; MALE; NAIL; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS FUNCTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUINAZOLINES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TAXOIDS;

EID: 77955822804     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR Gallinger S et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
4. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
5. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S et al: Raltitrexedeloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94(6): 785-791, 2006.
6. Kang SP and Saif MW: Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP 9(2): 83-90, 2008.
7. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51(18): 4845-4852, 1991.
8. Rougier P, Ducreux M, deForni M et al: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36(8): 1016-1025, 2000. (Pubitemid 30316427)
9. Lenzi R, Yalcin S, Evans DB and Abbruzzese JL: Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20(4): 464-472, 2002. (Pubitemid 34686342)
10. Androulakis N, Kourousis C, Dimopoulos MA et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17(6): 1779-1785, 1999.
11. Okada S, Sakata Y, Matsuno S et al: Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 80(3-4): 438-443, 1999. (Pubitemid 29213197)
12. Tabernero J, Climent MA, Lluch A et al: A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15(9): 2358-2365, 2004.
13. Camps C, Massud B, Jimenez A et al: Spanish Lung Cancer Group; Ramdomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17(3): 467-472, 2006.
14. Schuette W, Nagel S, Blankenburg T et al: Phase IH study of second-line chemotherapy for advanced non-small cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23(33): 8389-8395, 2005.
15. Gridelli C, Gallo C, DiMaio M et al: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 Study. Br J Cancer 91(12): 1996-2004, 2004.
16. Therasse P, Arbuck SG, Eisenhauer EA et al: New guide-lines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.
17. Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff IH: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8(2): 147-159, 1990.
18. Oudard S, Banu E, Beuzebox P et al: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23(15): 3343-3351, 2005.
19. Cereda S and Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabinerefractory metastatic pancreatic cancer. J Chemother 20(4): 509-512, 2008.
20. Hotchkiss KA, Ashton AW, Mahmood Russell RG, Sparano JA and Schwartz EL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ter 7(6): 855-859, 2002.
21. Ouettle H, Arnold D, Esser M, Huhn D and Riess H: Pachlitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anti-Cancer Drugs 11(10): 635-638, 2000.
22. Reni M, Pasetto L, Aprile G et al: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine resistant metastatic pancreatic cancer. Br J Cancer 94(6): 785-791, 2006.
23. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J and Hidalgo M: SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 27: 15s, 2009 (suppl; abstr 4525).
24. Desai N, Trieu V, Yao Z et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4): 1317-1324, 2006.